Literature proposes several meta-analyses which evaluate the efficacy of PARP inhibitors both as maintenance therapy after first line chemotherapy (8) as maintenance therapy in platinum-sensitive recurrence (10) confirming the recommendation for the use of PARP inhibitors in patients with ovarian cancer, albeit with different levels of benefit based on the HRD phenotype. Here, PARP1 is linked to ovarian carcinoma.